PL2491029T3 - Pochodne glikozydowe oraz ich zastosowania - Google Patents

Pochodne glikozydowe oraz ich zastosowania

Info

Publication number
PL2491029T3
PL2491029T3 PL10768927T PL10768927T PL2491029T3 PL 2491029 T3 PL2491029 T3 PL 2491029T3 PL 10768927 T PL10768927 T PL 10768927T PL 10768927 T PL10768927 T PL 10768927T PL 2491029 T3 PL2491029 T3 PL 2491029T3
Authority
PL
Poland
Prior art keywords
glycoside derivatives
glycoside
derivatives
Prior art date
Application number
PL10768927T
Other languages
English (en)
Inventor
Gregory Raymond Bebernitz
Mark G Bock
Dumbala Srinivas Reddy
Atul Kashinath Hajare
Vinod Vyavahare
Sandeep Bhausaheb Bhosale
Suresh Eknath Kurhade
Videsh Salunkhe
Nadim S Shaikh
Debnath Bhuniya
P Venkata Palle
Lili Feng
Jessica Liang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2491029(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2491029T3 publication Critical patent/PL2491029T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
PL10768927T 2009-10-20 2010-10-19 Pochodne glikozydowe oraz ich zastosowania PL2491029T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN2173DE2009 2009-10-20
IN2689DE2009 2009-12-23
EP10768927.5A EP2491029B1 (en) 2009-10-20 2010-10-19 Glycoside derivatives and uses thereof
PCT/EP2010/065747 WO2011048112A1 (en) 2009-10-20 2010-10-19 Glycoside derivatives and uses thereof

Publications (1)

Publication Number Publication Date
PL2491029T3 true PL2491029T3 (pl) 2016-07-29

Family

ID=43216622

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10768927T PL2491029T3 (pl) 2009-10-20 2010-10-19 Pochodne glikozydowe oraz ich zastosowania

Country Status (39)

Country Link
US (7) US8163704B2 (pl)
EP (1) EP2491029B1 (pl)
JP (2) JP5384744B2 (pl)
KR (2) KR101465308B1 (pl)
CN (1) CN102656165B (pl)
AR (1) AR078685A1 (pl)
AU (1) AU2010309833B2 (pl)
BR (1) BR112012009053B1 (pl)
CA (1) CA2777812C (pl)
CL (1) CL2012000991A1 (pl)
CO (1) CO6531486A2 (pl)
CR (1) CR20120176A (pl)
CU (1) CU24079B1 (pl)
CY (1) CY1117409T1 (pl)
DK (1) DK2491029T3 (pl)
EA (1) EA023781B1 (pl)
EC (1) ECSP12011909A (pl)
ES (1) ES2564191T3 (pl)
GT (1) GT201200117A (pl)
HN (1) HN2012000798A (pl)
HR (1) HRP20160436T1 (pl)
HU (1) HUE027531T2 (pl)
IL (1) IL219309A (pl)
JO (1) JO3152B1 (pl)
MA (1) MA33737B1 (pl)
MX (1) MX2012004700A (pl)
MY (1) MY158326A (pl)
NZ (1) NZ598717A (pl)
PE (1) PE20121281A1 (pl)
PH (1) PH12012500518A1 (pl)
PL (1) PL2491029T3 (pl)
RS (1) RS54563B1 (pl)
SG (1) SG179562A1 (pl)
SI (1) SI2491029T1 (pl)
TN (1) TN2012000109A1 (pl)
TW (2) TWI594756B (pl)
UY (1) UY32958A (pl)
WO (1) WO2011048112A1 (pl)
ZA (1) ZA201201680B (pl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2411393B1 (en) 2009-03-23 2014-01-22 Glenmark Pharmaceuticals S.A. Fused pyrimidine-dione derivatives as trpa1 modulators
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
US8163704B2 (en) * 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
CN102134226B (zh) * 2010-01-26 2013-06-12 天津药物研究院 一类苯基c-葡萄糖苷衍生物、其制备方法和用途
LT2568988T (lt) 2010-05-11 2016-09-12 Janssen Pharmaceutica, N.V. Farmacinės kompozicijos, apimančios 1-(beta-d-gliukopiranozil)-2-tienilmetilbenzeno darinius kaip sglt inhibitorius
KR101913587B1 (ko) 2011-04-13 2018-10-31 얀센 파마슈티카 엔.브이. Sglt2의 억제제로서 유용한 화합물의 제조 방법
WO2012140596A1 (en) * 2011-04-14 2012-10-18 Novartis Ag Glycoside derivatives and uses thereof
US8614195B2 (en) * 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
CN103596564B (zh) 2011-06-01 2016-05-04 株式会社绿十字 作为sglt2抑制剂的二苯基甲烷衍生物
CN102827122B (zh) * 2011-06-17 2015-01-14 山东轩竹医药科技有限公司 糖苷衍生物
CN102863417B (zh) * 2011-07-09 2015-01-14 山东轩竹医药科技有限公司 C-糖苷衍生物
TWI589576B (zh) * 2011-07-15 2017-07-01 諾華公司 氮雜－雙環二芳基醚之鹽類及製造彼等或其前驅物之方法
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
UA113086C2 (xx) 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
EP2968258B1 (en) * 2013-03-11 2020-02-12 Janssen Pharmaceutica NV Dual sglt1/sglt2 inhibitors
EP3010586A1 (en) 2013-06-21 2016-04-27 Lupin Limited Substituted heterocyclic compounds as crac modulators
AU2014300629A1 (en) 2013-06-24 2015-12-24 Lupin Limited Chromane and chromene derivatives and their use as CRAC modulators
CN104250272B (zh) * 2013-06-27 2018-10-09 上海方楠生物科技有限公司 一种利用微反应器制备列净类药物中间体的方法
CN107311992B (zh) * 2013-09-09 2020-08-18 上海研健新药研发有限公司 C-芳基葡糖苷衍生物、其制备方法及其在医药上的应用
AR098670A1 (es) 2013-11-08 2016-06-08 Lilly Co Eli Inhibidor de sglt1
CN104031098A (zh) * 2014-06-21 2014-09-10 李友香 降糖药物
CN104017031A (zh) * 2014-06-21 2014-09-03 李友香 降血糖药物和组合物
CN105294624B (zh) * 2015-11-16 2018-01-12 山东罗欣药业集团股份有限公司 一种达格列净的制备方法
SG11201811154QA (en) 2016-06-17 2019-01-30 Daewoong Pharmaceutical Co Ltd Method for producing diphenylmethane derivative
WO2018089449A1 (en) * 2016-11-10 2018-05-17 Janssen Pharmaceutica Nv Benzocyclobutane derivatives useful as dual sglt1/sglt2 modulators
CN108203432B (zh) * 2016-12-20 2021-03-02 宜昌东阳光长江药业股份有限公司 吡喃葡萄糖基衍生物及其在医药上的应用
TW201834663A (zh) * 2017-03-03 2018-10-01 瑞士商諾華公司 Sglt1/2抑制劑之給藥方案
JP2019517459A (ja) * 2017-04-12 2019-06-24 ノバルティス アーゲー 心不全患者におけるｌｉｋ０６６の使用
KR20200017487A (ko) * 2017-06-21 2020-02-18 노파르티스 아게 비알코올성 지방간염 치료를 위한 리코플리고진
US10696662B2 (en) 2017-08-21 2020-06-30 Janssen Pharmaceutica Nv 5-fluoro-C-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators
GB201721957D0 (en) * 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
GB201721961D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
GB201721964D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
GB201721960D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
GB201721967D0 (en) 2017-12-27 2018-02-07 Bp Oil Int Methods for preparing fuel additives
JP7555327B2 (ja) 2018-07-25 2024-09-24 ノバルティス アーゲー Ｎｌｒｐ３インフラマソーム阻害剤
CN108863736A (zh) * 2018-07-27 2018-11-23 福州大学 一种羰基功能化的芳香羧酸的制备方法
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
WO2020151620A1 (zh) * 2019-01-24 2020-07-30 北京盈科瑞创新药物研究有限公司 化合物、其制备方法及其作为药物中间体的应用
WO2020151623A1 (zh) * 2019-01-24 2020-07-30 北京盈科瑞创新药物研究有限公司 化合物、其制备方法及其作为药物中间体的应用
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CA3142905A1 (en) 2019-07-23 2021-01-28 Novartis Ag Combination treatment of liver diseases using fxr agonists
CN111099975A (zh) * 2019-12-23 2020-05-05 河北合佳医药科技集团股份有限公司 一种5-溴-2-氯-4’-乙氧基二苯甲酮的制备方法
WO2022105845A1 (zh) * 2020-11-19 2022-05-27 北京盈科瑞创新药物研究有限公司 一种糖苷类衍生物及其制备方法和应用
KR20220080880A (ko) * 2020-12-08 2022-06-15 주식회사 종근당 엠파글리플로진 공결정을 함유하는 약제학적 조성물
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1020944C (zh) 1990-01-30 1993-05-26 阿图尔-费希尔股份公司费希尔厂 紧固件
US5410031A (en) * 1992-02-24 1995-04-25 The Regents Of The University Of California Office Of Technology Transfer Nucleoside cotransporter protein cDNA
US5410054A (en) 1993-07-20 1995-04-25 Merck Frosst Canada, Inc. Heteroaryl quinolines as inhibitors of leukotriene biosynthesis
WO1998031697A1 (en) 1997-01-15 1998-07-23 Sankyo Company, Limited Aryl c-glycoside compounds and sulfated esters thereof
KR100591585B1 (ko) 1999-08-31 2006-06-20 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실옥시피라졸 유도체, 그것을 함유하는 의약조성물 및 그 제조 중간체
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
JP4272319B2 (ja) * 1999-11-30 2009-06-03 アイシン精機株式会社 ヘッドレスト装置
US6627611B2 (en) * 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
JP4456768B2 (ja) 2000-02-02 2010-04-28 壽製薬株式会社 Ｃ−配糖体を含有する薬剤
BR0109323A (pt) 2000-03-17 2002-12-24 Kissei Pharmaceutical Derivados de gluco piranosiloxi benzil benzeno, composições medicinais contendo os mesmos e intermediários para a preparação dos derivados
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
CN1293087C (zh) 2000-09-29 2007-01-03 橘生药品工业株式会社 吡喃葡糖氧基苄基苯衍生物及其药物组合物
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
ES2321815T3 (es) * 2001-04-04 2009-06-12 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Combinacion terapeutica que comprende inhibidores de reabsorcion e glucosa y moduladores ppar.
ATE442148T1 (de) 2001-04-04 2009-09-15 Ortho Mcneil Janssen Pharm Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren
EP1432720A1 (en) 2001-09-05 2004-06-30 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
DE10231370B4 (de) 2002-07-11 2006-04-06 Sanofi-Aventis Deutschland Gmbh Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
EP1568380A4 (en) 2002-12-04 2009-10-21 Kissei Pharmaceutical PREVENTION OR TREATMENT OF DISEASES DUE TO HYPERGLYCEMIA
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
EP1444890B1 (en) 2003-02-05 2009-01-07 Hermann Koepsell RS1 deficient transgenic animal and uses thereof
JP4222450B2 (ja) 2003-03-14 2009-02-12 アステラス製薬株式会社 Ｃ−グリコシド誘導体又はその塩
AU2003902263A0 (en) 2003-05-12 2003-05-29 Fujisawa Pharmaceutical Co., Ltd. Monosaccharide compounds
RS20060320A (sr) 2003-08-01 2008-08-07 Janssen Pharmaceutica N.V., Supstituisani indazol-o-glukozidi
RS53365B (sr) 2003-08-01 2014-10-31 Mitsubishi Tanabe Pharma Corporation Nova jedinjenja koja imaju inhibitorno dejstvo na transporter glukoze zavisan od natrijuma
CA2539032A1 (en) 2003-08-26 2005-03-10 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pirazoles, drugs containing said compounds the use and production method thereof
AU2005219779B2 (en) 2004-03-04 2011-04-14 Kissei Pharmaceutical Co., Ltd. Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
PL381247A1 (pl) 2004-03-04 2007-05-14 Kissei Pharmaceutical Co., Ltd. Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja lecznicza, oraz jej zastosowanie lecznicze
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
DE102004034690A1 (de) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CA2574451A1 (en) * 2004-07-27 2006-02-02 Boehringer Ingelheim International Gmbh D-glucopyranosyl phenyl-substituted cyclene, medicaments containing these compounds, their use, and method for the production thereof
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
ATE469653T1 (de) 2004-09-22 2010-06-15 Vib Vzw Inhibitoren der geschmacksrezeptoren zur verwendung in der behandlung von fettleibigkeit und zuckerkrankheit
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
CA2588963C (en) 2004-11-18 2013-06-25 Kissei Pharmaceutical Co., Ltd. 1-substituted-3-.beta.-d-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
US7803778B2 (en) * 2006-05-23 2010-09-28 Theracos, Inc. Glucose transport inhibitors and methods of use
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
WO2008115574A1 (en) 2007-03-21 2008-09-25 Reliant Pharmaceuticals, Inc. Cb1 antagonist and a dyslipidemic agent and/or metabolic regulator, and methods of making and using same
TW200904454A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
BRPI0810409A2 (pt) 2007-04-18 2015-02-18 Thethys Bioscience Inc Biomarcadores relacionados ao diabetes e métodos de uso destes
WO2009026389A2 (en) 2007-08-20 2009-02-26 Mount Sinai School Of Medicine Regulating glp-1 and sglt-1 in gastrointestinal cells
UA99924C2 (en) 2007-08-23 2012-10-25 Теракос, Инк. Benzylbenzol derivatives and using thereof
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
KR101516677B1 (ko) * 2008-01-31 2015-05-04 고토부키 세이야쿠 가부시키가이샤 지방성 간 질환의 치료용 의약 조성물
US8791077B2 (en) 2008-05-22 2014-07-29 Astrazeneca Ab Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same
US8603989B2 (en) 2008-05-22 2013-12-10 Bristol-Myers Squibb Company Method for treating and preventing kidney stones employing an SGLT2 inhibitor and composition containing same
US8518895B2 (en) 2008-05-22 2013-08-27 Bristol-Myers Squibb Company Method for treating hyponatremia employing an SGLT2 inhibitor and composition containing same
EA201100503A1 (ru) 2008-09-19 2011-10-31 Новартис Аг Глюкозидные производные и их применения
EP2342187A1 (en) 2008-09-19 2011-07-13 Novartis AG Glycoside derivatives and uses thereof
WO2010045656A2 (en) 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
WO2010048358A2 (en) 2008-10-22 2010-04-29 Auspex Pharmaceutical, Inc. Ethoxyphenylmethyl inhibitors of sglt2
WO2010074219A1 (ja) 2008-12-26 2010-07-01 アステラス製薬株式会社 ベンゾチオフェン化合物
US20120035105A1 (en) 2009-01-09 2012-02-09 Sdg, Inc. Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
SG173619A1 (en) 2009-02-13 2011-09-29 Boehringer Ingelheim Int Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
BRPI1013640A2 (pt) 2009-02-13 2019-09-24 Boehringer Ingelheim Int composicao farmaceutica, metodos para o tratamento e usos dos mesmos
WO2010128152A1 (en) * 2009-05-07 2010-11-11 Novartis Ag Fused heterocyclic c-glycosides for the treatment of diabetes
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof

Also Published As

Publication number Publication date
CR20120176A (es) 2012-05-22
EA201200600A1 (ru) 2012-12-28
PE20121281A1 (es) 2012-10-05
NZ598717A (en) 2014-04-30
DK2491029T3 (en) 2016-04-11
US9895389B2 (en) 2018-02-20
SG179562A1 (en) 2012-05-30
SI2491029T1 (sl) 2016-05-31
BR112012009053A2 (pt) 2016-04-19
KR20120083484A (ko) 2012-07-25
IL219309A0 (en) 2012-06-28
JP2013508335A (ja) 2013-03-07
JO3152B1 (ar) 2017-09-20
EA023781B1 (ru) 2016-07-29
CA2777812C (en) 2018-07-17
TWI558723B (zh) 2016-11-21
TWI594756B (zh) 2017-08-11
TW201118104A (en) 2011-06-01
US8828951B2 (en) 2014-09-09
JP2014040451A (ja) 2014-03-06
US20130017993A1 (en) 2013-01-17
US8466114B2 (en) 2013-06-18
AU2010309833B2 (en) 2014-06-12
CN102656165B (zh) 2015-02-11
JP5384744B2 (ja) 2014-01-08
US8163704B2 (en) 2012-04-24
EP2491029B1 (en) 2016-02-10
USRE49080E1 (en) 2022-05-24
MX2012004700A (es) 2012-05-23
GT201200117A (es) 2013-09-23
WO2011048112A1 (en) 2011-04-28
HUE027531T2 (en) 2016-10-28
US20140274921A1 (en) 2014-09-18
AU2010309833A1 (en) 2012-03-29
RS54563B1 (sr) 2016-06-30
KR20140054415A (ko) 2014-05-08
BR112012009053B1 (pt) 2020-03-03
TN2012000109A1 (en) 2013-09-19
MY158326A (en) 2016-09-30
HRP20160436T1 (hr) 2016-05-20
TW201632190A (zh) 2016-09-16
CU20120062A7 (es) 2012-06-29
CA2777812A1 (en) 2011-04-28
CU24079B1 (es) 2015-03-30
US20120178680A1 (en) 2012-07-12
HN2012000798A (es) 2015-08-03
CN102656165A (zh) 2012-09-05
EP2491029A1 (en) 2012-08-29
UY32958A (es) 2011-05-31
PH12012500518A1 (en) 2016-05-20
ES2564191T3 (es) 2016-03-18
CO6531486A2 (es) 2012-09-28
US20110171159A1 (en) 2011-07-14
US20170042925A1 (en) 2017-02-16
AR078685A1 (es) 2011-11-23
ECSP12011909A (es) 2012-07-31
IL219309A (en) 2015-03-31
CY1117409T1 (el) 2017-04-26
CL2012000991A1 (es) 2012-09-07
US20150141354A1 (en) 2015-05-21
HK1168099A1 (zh) 2012-12-21
MA33737B1 (fr) 2012-11-01
ZA201201680B (en) 2012-11-28
KR101465308B1 (ko) 2014-11-28

Similar Documents

Publication Publication Date Title
IL219309A0 (en) Glycoside derivatives and uses thereof
ZA201109034B (en) Aminopyrrolidinone derivatives and uses thereof
SG173666A1 (en) Isoxazole-isoxazole and isoxazole-isothiazole derivatives
IL211042A0 (en) Imidazopyridin-2-one derivatives and uses thereof
ZA201103635B (en) Azaquinolinone derivatives and uses thereof
IL219087A0 (en) Benzimidazole-imidazole derivatives
IL217956A0 (en) N1-sulfonyl-5-fluoropyrimidinone derivatives
IL217953A0 (en) 5-fluoropyrimidinone derivatives
IL216007A0 (en) Isoxazole-pyridine derivatives
IL215109A0 (en) Isoxazole-pyridazine derivatives
IL214941A0 (en) Isoxazole-pyrazole derivatives
IL217952A0 (en) N1-acyl-5-fluoropyrimidinone derivatives
IL213927A0 (en) Deoxyactagardine derivatives
IL216761A0 (en) Pyrazinooxazepine derivatives
ZA201200860B (en) New macrolides and their use
IL220427A (en) Tertiary history of 8-hydroxyquinoline-7-carboxamide and their use
EP2460812A4 (en) STEROL DERIVATIVES AND THEIR SYNTHESIS AND USE
GB0912744D0 (en) Methods and uses
EP2274294A4 (en) 5-DIMETHOXY FUMAGILLOL AND ITS DERIVATIVES
IL206951A0 (en) 3-alkyl-piperazine derivatives and uses thereof
GB0909792D0 (en) Composition and uses thereof
IL213262A0 (en) Tetrahydronaphthalen-2-ol derivatives
GB0905525D0 (en) Compounds and uses
GB0912499D0 (en) Indopyl-pyridone derivatives
HK1168348A (en) Aminopyrrolidinone derivatives and uses thereof